Impact of P53 and SIRT1 in Type 2 Diabetes

Launched by SHERIEF ABD-ELSALAM · Apr 22, 2019

Keywords

ClinConnect Summary

This clinical trial is looking at how two specific proteins, p53 and SIRT1, might affect the development of type 2 diabetes. Researchers want to understand if these proteins play a role in helping people who are at risk of developing diabetes, specifically those who are in a prediabetic state. This means they have higher than normal blood sugar levels but are not yet diagnosed with diabetes.

To join the study, participants should be between the ages of 65 and 74 and currently in a prediabetic condition. However, individuals with confirmed diabetes or those with liver or kidney problems cannot take part in this trial. If you join, you can expect to undergo various tests and assessments to help researchers gather important information about how p53 and SIRT1 might influence blood sugar levels. This study is currently actively seeking participants, so if you fit the criteria and are interested, it could be a great opportunity to contribute to important diabetes research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Prediabetic subjects.
• Exclusion Criteria:
• • Confirmed diabetes.
• • Hepatic or renal impairment.